» Articles » PMID: 18697775

Rheumatoid Arthritis Versus Diabetes As a Risk Factor for Cardiovascular Disease: a Cross-sectional Study, the CARRE Investigation

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2008 Aug 14
PMID 18697775
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk, but the magnitude of this risk is not known precisely. A study was undertaken to investigate the associations between RA and type 2 diabetes (DM2), a well-established cardiovascular risk factor, on the one hand, and cardiovascular disease (CVD) on the other.

Methods: The prevalence of CVD (coronary, cerebral and peripheral arterial disease) was determined in 353 randomly selected outpatients with RA (diagnosed between 1989 and 2001, aged 50-75 years; the CARRE study) and in participants of a population-based cohort study on diabetes and CVD (the Hoorn study). Patients with RA with normal fasting glucose levels from the CARRE study (RA, n = 294) were compared with individuals from the Hoorn study with normal glucose metabolism (non-diabetic, n = 258) and individuals with DM2 (DM2, n = 194).

Results: The prevalence of CVD was 5.0% (95% CI 2.3% to 7.7%) in the non-diabetic group, 12.4% (95% CI 7.5% to 17.3%) in the DM2 group and 12.9% (95% CI 8.8% to 17.0%) in those with RA. With non-diabetic individuals as the reference category, the age- and gender-adjusted prevalence odds ratio (OR) for CVD was 2.3 (95% CI 1.1 to 4.7) for individuals with DM2 and 3.1 (95% CI 1.6 to 6.1) for those with RA. There was an attenuation of the prevalences after adjustment for conventional cardiovascular risk factors (OR 2.0 (95% CI 0.9 to 4.5) and 2.7 (95% CI 1.2 to 5.9), respectively).

Conclusions: The prevalence of CVD in RA is increased to an extent that is at least comparable to that of DM2. This should have implications for primary cardiovascular prevention strategies in RA.

Citing Articles

The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations.

Avouac J, Ait-Oufella H, Habauzit C, Benkhalifa S, Combe B Rheumatol Ther. 2025; .

PMID: 40019616 DOI: 10.1007/s40744-025-00753-x.


Aspirin does not confer protection against major ischemic vascular events in patients diagnosed with rheumatoid arthritis.

Gao C, Hou Q, Cao H, Li C, Peng X, Han Q J Int Med Res. 2025; 53(2):3000605251315359.

PMID: 39917854 PMC: 11806481. DOI: 10.1177/03000605251315359.


Cerebrovascular risk in rheumatoid arthritis patients: insights from carotid artery atherosclerosis in the Paracelsus 10,000 study.

Ausserwinkler M, Gensluckner S, Frey V, Gostner I, Paulweber B, Trinka E Rheumatol Int. 2025; 45(2):33.

PMID: 39825928 PMC: 11742769. DOI: 10.1007/s00296-024-05781-4.


Haptoglobin 2-2 genotype is associated with increased risk of cardiovascular disease in patients with rheumatoid arthritis: a matched case-control study.

Xu C, Khin L, Tam H, Goh L, Koh E, Dalan R Front Med (Lausanne). 2025; 11:1442858.

PMID: 39741512 PMC: 11685008. DOI: 10.3389/fmed.2024.1442858.


Hypertension, diabetes, and cardiovascular disease nexus: investigating the role of urbanization and lifestyle in Cabo Verde.

Christian A, Osei-Appaw A, Sawyerr R, Agyekum M Glob Health Action. 2024; 17(1):2414524.

PMID: 39435468 PMC: 11639676. DOI: 10.1080/16549716.2024.2414524.